Skip to main content
3D Medicines Inc. logo

3D Medicines Inc. — Investor Relations & Filings

Ticker · 1244 ISIN · KYG8872R1011 HKEX Manufacturing
Open in API
Filings indexed 149 across all filing types
Latest filing 2026-06-05 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 1244

About 3D Medicines Inc.

https://www.3d-medicines.com

3D Medicines Inc. is an oncology-focused, commercial-stage biopharmaceutical company specializing in the development and commercialization of next-generation immuno-oncology therapies. The company leverages global research and development capabilities and internal discovery platforms to advance a pipeline of innovative drug candidates. Its core mission is to address unmet medical needs in cancer treatment, aiming to transform cancer into a chronic disease and provide substantial value to patients and healthcare providers globally.

Recent filings

Filing Released Lang Actions
Form of proxy for the Annual General Meeting to be held on Tuesday, June 30, 2026
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form of Proxy for the Annual General Meeting, used to solicit shareholder votes and provide meeting resolution details. This fits the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to request votes for meetings.
2026-06-05 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal Notice of the Annual General Meeting of 3D Medicines Inc., outlining meeting details, resolutions to be voted on, proxy appointment instructions, record dates, and related shareholder voting procedures. It is not the AGM slide deck or presentation itself (AGM-R), nor an annual report or earnings release. Instead, it is a solicitation of proxies and information statement for the upcoming shareholder meeting. Therefore, it falls under Proxy Solicitation & Information Statement (PSI).
2026-06-05 English
GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; RE-APPOINTMENT OF AUDITOR; AND NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a shareholder circular relating to the upcoming Annual General Meeting: it includes general mandates to issue/repurchase shares, re-election of directors, re-appointment of auditor, a Notice of AGM, and proxy instructions. This is classic proxy solicitation material and an information statement sent to shareholders ahead of a vote, matching the Proxy Solicitation & Information Statement category (PSI).
2026-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Regulatory Filings Classification · 87% confidence The document is a statutory monthly return (Form FF301) filed with the Hong Kong Stock Exchange under Listing Rule Chapter 19B, detailing movements in authorized share capital, issued shares, share options, and public float confirmations. It is not a narrative or financial report (Annual, Interim, Earnings Release, etc.), nor is it an AGM presentation or proxy statement. It is a regulatory compliance filing and does not announce a specific new share issue or capital change event. Therefore, it best fits the “Regulatory Filings” category (RNS).
2026-06-03 English
VOLUNTARY ANNOUNCEMENT PHASE III STUDY RESULTS OF ENVAFOLIMAB PLUS GEMOX IN FIRST-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER TO BE OFFICIALLY PRESENTED AT 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 88% confidence The document is a voluntary announcement by the company regarding the presentation of clinical trial Phase III results at an upcoming medical conference. It contains no financial statements, board changes, investor presentation slides, regulatory forms, or other specific filing content. It does not fit any specialized category (e.g., 10-K, IR, ER, MDA, IP, etc.) and is essentially a general company announcement. Therefore, it is classified under the fallback category Regulatory Filings (RNS).
2026-05-27 English
VOLUNTARY ANNOUNCEMENT EARLY COMPLETION OF ENROLLMENT IN THE PHASE III CLINICAL TRIAL OF ENVAFOLIMAB FOR NEOADJUVANT/ADJUVANT TREATMENT OF NON-SMALL CELL LUNG CANCER
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement regarding the early completion of patient enrollment in a Phase III clinical trial. It does not contain any financial statements, securities transactions, voting results, or formal report attachments; instead it is a general business update filed on an exchange. This falls under the broad “Regulatory Filings” category for miscellaneous announcements that do not match more specific categories.
2026-05-21 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.